2024-09-01 - Analysis Report
##  ABBV Stock Analysis Report

**Company Overview:** AbbVie Inc. (ABBV) is a multinational pharmaceutical company that develops, manufactures, and markets a broad range of medicines across various therapeutic areas, including immunology, oncology, neurology, and virology.

**Performance Summary:**

**1. Outperformance vs. S&P 500:**

* ABBV has outperformed the S&P 500 (VOO) significantly, with a cumulative return of 106.38% versus 89.66% for VOO.
* This outperformance translates to a difference of 16.72 percentage points, positioning ABBV at the 65.53 percentile of its historical performance relative to the S&P 500.

**2. Recent Price Movement:**

* ABBV's closing price is $196.31.
* The stock is trading slightly above its 5-day moving average ($196.05), suggesting short-term momentum.
* It is also trading above its 20-day ($193.17) and 60-day ($179.48) moving averages, indicating a possible uptrend.

**3. Technical Indicators:**

* The RSI (74.27) indicates that ABBV is in overbought territory, potentially suggesting a short-term correction may be imminent.
* The PPO (-0.36) is negative, suggesting a potential slowdown in price momentum.
* The recent 20-day Relative Divergence has been declining (-3.27), indicating a possible short-term price weakness. 
* Despite these signals, the 16.29% expected return suggests potential upside potential in the stock.

**4. Recent Earnings & Outlook:**

* ABBV's recent earnings have been consistently beating expectations. 
* The most recent earnings report for the quarter ending July 25, 2024, showed an EPS of $2.65, surpassing the estimated $2.57.
* This consistent outperformance indicates strong underlying business performance and positive investor sentiment.

**5. Overall Analysis:**

ABBV has been a strong performer, consistently exceeding the S&P 500's returns. While technical indicators suggest potential short-term price weakness, strong earnings and a positive outlook suggest continued growth potential in the long term. Investors should be mindful of the overbought RSI reading and the potential for a near-term correction, but the stock remains a strong candidate for long-term investment.

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.